INTELLECTUAL PROPERTY SECURITY AGREEMENT

EX-10.20 32 d443122dex1020.htm EX-10.20 EX-10.20

Exhibit 10.20

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the Effective Date by and between OXFORD FINANCE LLC, as collateral agent for the Lenders (the “Lenders”) described in the Loan Agreement (in such capacity, the “Collateral Agent”) and PROTOX THERAPEUTICS INC. (“Grantor”).

RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “Loans”) in the amounts and manner set forth in that certain Loan and Security Agreement by and among Collateral Agent, the Lenders, Protox Therapeutics Corp. and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the “Loan Agreement”; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a continuing security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

New York law governs this Intellectual Property Security Agreement without regard to principles of conflicts of law. This Intellectual Property Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one agreement.

[Balance of Page Intentionally Left Blank]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

 

GRANTOR:      
Address of Grantor:     PROTOX THERAPEUTICS, INC.
1500 – 885 West Georgia Street,     By:  

/s/ A. Hulme

Vancouver, British Columbia, Canada, V6C 3E8      
Attn: Chief Financial Officer     Title:  

Chief Operating Officer

    COLLATERAL AGENT:
Address of Lender:     OXFORD FINANCE LLC
133 North Fairfax Street     By:  

/s/ TAZ

Alexandria, Virginia 22314      
Attn: General Counsel     Title:  

COO

[Signature Page to Intellectual Property Security Agreement]


EXHIBIT A

Copyrights

 

Description

  

Registration Number

  

Registration Date

None.

     


EXHIBIT B

Patents

 

Description

  

Patent/App. No.

  

File Date

   Country
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    2002331720    8/23/02    Australia
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    2,457,903    8/23/02    Canada
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    2816622.1    8/23/02    China
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    2768702.9    8/23/02    EPC
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    TBD (divisional)    8/23/02    EPC
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    2003-523270    8/23/02    Japan
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    10/487,115    2/18/04    U.S.
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    11/856,543    9/17/07    U.S.
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    12/788,913    5/27/10    U.S.
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    2004/02319    8/23/02    South Africa
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    00379/KOLNP/04    8/23/02    India
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer    2389/KOLNP/2007    3/22/04    India
Modified pore-forming protein toxins and use thereof    12/094,597    11/21/06    U.S.
Modified pore-forming protein toxins and use thereof    2630559    11/21/06    Canada
Modified pore-forming protein toxins and use thereof    6804758.8    11/21/06    EPC
Modified pore-forming protein toxins and use thereof    11166965.1    5/20/11    EPC
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins    2006257664    6/14/06    Australia
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins    2,611,839    6/14/06    Canada


Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   200680028473.6   6/14/06   China
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   6761050.1   6/14/06   EPC
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   188143   6/14/06   Israel
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   2008-516088   6/14/06   Japan
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   564954   6/14/06   New Zealand
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   200718733-9   6/14/06   Singapore
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   11/921,964   12/10/07   U.S.
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   10 ###-###-####   6/14/06   Korea
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins   2007/10813   6/14/06   South Africa
Method for treating prostatitis utilizing modified pore-forming protein proaerolysin   PCT/CA2009/001837   12/15/09   PCT
Circularly permuted ligands and circularly permuted chimeric molecules   08/225,224   6/03/97   U.S.
Circularly permuted ligands and circularly permuted chimeric molecules   1995022857   11/5/98   Australia
Circularly permuted ligands and circularly permuted chimeric molecules   2,187,283   9/23/08   Canada
Circularly permuted ligands and circularly permuted chimeric molecules   95916319.7   1/29/03   EPC
Circularly permuted ligands and circularly permuted chimeric molecules   08/722,258   12/10/07   U.S.
Convection enhanced drug delivery   616,785   2/24/98   U.S.
Method for convection enhanced delivery of therapeutic agents   2003299140   9/24/03   Australia
Method for convection enhanced delivery of therapeutic agents   2,499,573   9/24/03   Canada
Method for convection enhanced delivery of therapeutic agents   3756863.1   9/24/03   EPC


Method for convection enhanced delivery of therapeutic agents   10/528,310   9/24/03   U.S.
Treating cancer stem cells using targeted cargo proteins   PCT/CA2009/001323   9/21/09   PCT
Treating cancer stem cells using targeted cargo proteins   13/119,426   3/16/11   U.S.
Targeted cargo protein combination therapy   12/579,281   10/14/09   U.S.
Use of human serum albumin to decrease antigenicity of therapeutic proteins   61/406,052   10/22/10   U.S. Provisional
Methods and compositions for inhibiting cell death or enhancing cell proliferation   2,622,504   9/8/06   Canada
Methods and compositions for inhibiting cell death or enhancing cell proliferation   6851440.5   9/8/06   EPC
Methods and compositions for inhibiting cell death or enhancing cell proliferation   2008-536580   9/8/06   Japan
Methods and compositions for inhibiting cell death or enhancing cell proliferation   11/91,692   9/8/06   U.S.
Receptor-mediated uptake of an extracellular BCL-XL fusion protein inhibits apoptosis     5/15/04   U.S.
Receptor-mediated uptake of an extracellular BCL-XL fusion protein inhibits apoptosis   12/147,924   6/27/08   U.S. Divisional


EXHIBIT C

Trademarks

 

Description

  

Serial/Registration No.

  

File Date

None.